Barriers and enablers to implementing antenatal magnesium sulphate for fetal neuroprotection guidelines: A study using the theoretical domains framework

BMC Pregnancy and Childbirth

Volumn 15, Issue 1, 2015, Pages

  Bain, Emily ^a   Bubner, Tanya ^a   Ashwood, Pat ^a   Van Ryswyk, Emer ^a   Simmonds, Lucy ^a   Reid, Sally ^a,b   Middleton, Philippa ^a   Crowther, Caroline A ^a,c  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

MAGNESIUM SULFATE; NEUROPROTECTIVE AGENT;

ARTICLE; ATTENTION; AUSTRALIA; CONCEPTUAL FRAMEWORK; DRUG USE; FETAL WELL BEING; HEALTH BELIEF; HEALTH EDUCATION; HEALTH PRACTITIONER; HUMAN; MEDICAL DECISION MAKING; MEDICAL STUDENT; MEMORY; MIDWIFE; NEONATOLOGIST; NEUROPROTECTION; NEW ZEALAND; OBSTETRICIAN; PRACTICE GUIDELINE; PREMATURITY; PRENATAL CARE; PROFESSIONAL COMPETENCE; PROFESSIONAL KNOWLEDGE; SEMI STRUCTURED INTERVIEW; SOCIAL ASPECT; STAFF TRAINING; UNSPECIFIED SIDE EFFECT; CEREBRAL PALSY; CLINICAL COMPETENCE; FEMALE; HEALTH PERSONNEL ATTITUDE; NEONATOLOGY; NEWBORN; OBSTETRICS; PERINATAL DEATH; PREGNANCY; PREVENTION AND CONTROL; PROTOCOL COMPLIANCE; REMINDER SYSTEM; SOUTH AUSTRALIA; STATISTICS AND NUMERICAL DATA; TIME FACTOR;

ATTITUDE OF HEALTH PERSONNEL; CEREBRAL PALSY; CLINICAL COMPETENCE; FEMALE; GUIDELINE ADHERENCE; HUMANS; INFANT, EXTREMELY PREMATURE; INFANT, NEWBORN; INFANT, PREMATURE; MAGNESIUM SULFATE; MIDWIFERY; NEONATOLOGY; NEUROPROTECTIVE AGENTS; OBSTETRICS; PERINATAL DEATH; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREMATURE BIRTH; REMINDER SYSTEMS; SOUTH AUSTRALIA; TIME FACTORS;

EID: 84939450047     PISSN: None     EISSN: 14712393     Source Type: Journal    
DOI: 10.1186/s12884-015-0618-9     Document Type: Article

References (28)

1. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet. 2008;371(9606):75-84.
2. Saigal S, Doyle L. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet. 2008;371(9608):261-9.
3. Australian Cerebral Palsy Register Group: Report of the Australian Cerebral Palsy Register, Birth Years 1993-2006. Cerebral Palsy Alliance Research Institute. Sydney; 2013.
4. McIntyre S, Novak I, Cusick A. Consensus research priorities for cerebral palsy: a Delphi survey of consumers, researchers, and clinicians. Dev Med Child Neurol. 2010;52(3):270-5.
5. Nelson KB, Grether JK. Can magnesium sulphate reduce the risk of cerebral palsy in very low birthweight infants? Paediatr. 1995;95(2):263-9.
6. Crowther CA, Hiller JE, Doyle LW, Haslam RR. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA. 2003;290:2669-76.
7. Marret S, Marpeau L, Zupan-Simunek V, Eurin D, Lévêque C, Hellot MF, et al. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial. Br J Obstet Gynaecol. 2007;114:310-8.
8. Mittendorf R, Dambrosia J, Pryde PG, Lee K-S, Gianopoulos JG, Besinger RE, et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. Am J Obstet Gynecol. 2002;186:1111-8.
9. Rouse DJ, Hirtz DG, Thom E, Varner MW, Spong CY, Mercer BM, et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med. 2008;359:895-905.
10. Magpie Trial Follow-Up Study Collaborative Grou. The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for children at 18 months. Br J Obstet Gynaecol. 2007;114:289-99.
11. Doyle LW, Crowther CA, Middleton P, Marret S, Rouse DJ. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev. 2009;1, CD004661. doi: 10.1002/14651858.CD004661.pub3 .
12. Antenatal Magnesium Sulphate for Neuroprotection Guideline Development Panel. Antenatal magnesium sulphate prior to preterm birth for neuroprotection of the fetus, infant and child: National clinical practice guidelines. Adelaide: The University of Adelaide; 2010.
13. Mugford M. Corticosteroids in preterm delivery-estimated impact on neonatal outcomes and health service resources. In: A review of stillbirths and neonatal mortality in the Oxford Region. Oxford: Oxford Regional Health Authority; 1993. p. 37-40.
14. Penney G, Foy R. Do clinical guidelines enhance safe practice in obstetrics and gynaecology? Best Pract Res Clin Obstet Gynaecol. 2007;21(4):657-73.
15. Crowther CA, Middleton PF, Bain E, Ashwood P, Bubner T, Flenady V, et al. Working to improve survival and health for babies born very preterm: the WISH project protocol. BMC Pregnancy Childbirth. 2013;13:239.
16. Chaillet N, Dube E, Dugas M, Audibert F, Tourigny C, Fraser WD, et al. Evidence-based strategies for implementing guidelines in obstetrics: a systematic review. Obstet Gynecol. 2006;108(5):1234-45.
17. Cane J, O'Connor D, Michie S. Validation of the theoretical domains framework for use in behaviour change and implementation research. Implement Sci. 2012;7:37.
18. Michie S, Johnson M, Abraham C, Lawton R, Parker D, Walker A, et al. Making psychological theory useful for implementing evidence based practice: a consensus approach. BMC Pregnancy Childbirth. 2005;14(1):26-33.
19. Mazza D, Chapman A, Michie S. Barriers to the implementation of preconception care guidelines as perceived by general practitioners: a qualitative study. BMC Health Serv Res. 2013;13:36.
20. Heslehurts N, Newham J, Maniatopoulos G, Fleetwood C, Robalino S, Rankin J. Implementation of pregnancy weight management and obesity guidelines: a meta-analysis of healthcare professionals' barriers and facilitators using the Theoretical Domains Framework. Obes Rev. 2014;15(6):462-86.
21. Beenstock J, Sneihotta FF, White M, Bell R, Milne EM, Araujo-Soares V. What helps and hinders midwives in engaging with pregnant women about stopping smoking? A cross-sectional survey of perceived implementation difficulties among midwives in the North East of England. Implement Sci. 2012;7:36.
22. Bain E, Ashwood P, Middleton PF, Bubner T, Heatley E, Zhang Y, et al. Rapid implementation of antenatal magnesium sulphate for fetal neuroprotection at the WCH, Adelaide, Australia (2009-2012). J Paediatr Child Health. 2013;49 Suppl 2:OP036.
23. Women's and Children's Health Network: Women's and Children's Hospital. http://www.wch.sa.gov.au/ (2005). Accessed 29 Jun 2015.
24. Pope C, Ziebland S, Mays N. Qualitative research in health care. Analysing qualitative data. BMJ. 2000;320(7227):114-6.
25. Mills CE, Beckmann M, Flenady V, Bain E, Middleton P, Crowther CA. for the WISH Study Team. Implementing the bi-national guidelines on antenatal magnesium sulphate for fetal neuroprotection: factors influencing compliance at a large tertiary centre. J Paediatr Child Health. 2014;50 Suppl 1:S394.
26. Ow LL, Kennedy A, McCarthy EA, Walker SP. Feasibility of implementing magnesium sulphate for neuroprotection in a tertiary obstetric unit. Aust N Z J Obstet Gynaecol. 2012;52(4):356-60.
27. Siwicki K, Bain E, Ashwood P, Bubner T, Middleton P, Crowther CA. "There aren't too many that get away, are there?" Non-receipt of antenatal magnesium sulphate for fetal neuroprotection at the Women's and Children's Hospital, Adelaide 2010-13. J Paediatr Child Health. 2014;50 Suppl 1:A401.
28. Simpson KR, Knox GE. Obstetrical accidents involving intravenous magnesium sulfate: recommendations to promote patient safety. MCN Am J Matern Child Nurs. 2004;29:161-9.